Remove 2001 Remove Clinical Trials Remove Epilepsy
article thumbnail

SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study

Cannabis Law Report

(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain.

article thumbnail

UK Baker & McKenzie Article – United Kingdom: London’s First Medical Cannabis Clinic Opens to Waiting List

Cannabis Law Report

The opening of London’s first such clinic follows the opening of Britain’s first medical cannabis clinic in Greater Manchester earlier in the year. Access is clearly in demand from Londoners as there is already a waiting list of 150 patients at the London clinic ahead of its opening.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Lancet Neurol Dec 23 2015. Fabricio A.

article thumbnail

Cannabis laws in Japan: Is weed legal?

The Cannigma

In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes. Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition.

Law 140
article thumbnail

Pushing Cannabis into Modern Healthcare

CannaTech

Canada has been at the forefront of shaping much of the rhetoric surrounding cannabis since 2001. But this gap restricts patient access to a medicine that can offer relief to a long list of conditions including chronic pain, seizures attributed to epilepsy, as well as mood disorders such as anxiety and depression.

article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Refractory paediatric epilepsy. Only one article appeared in the MJA in 2000 and again in 2001. Conclusions. Palliative care indications. Cancer pain.

article thumbnail

Meritas Law Firms Worldwide Article: Global Cannabis Industry: The Essential Primer

Cannabis Law Report

Some of the potential health benefits associated with THC and CBD, with and without the high, respectively, include reducing chronic pain such as from migraines or cancer, alleviating anxiety, reducing inflammation, and helping treat conditions such as epilepsy, PTSD, and glaucoma. This is true even if the CBD comes from industrial hemp.

Law 40